Healthcare of Ontario Pension Plan Trust Fund Has $941,000 Position in Integra LifeSciences Holdings Corporation $IART

Healthcare of Ontario Pension Plan Trust Fund cut its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 49.1% during the 1st quarter, Holdings Channel.com reports. The firm owned 99,864 shares of the life sciences company’s stock after selling 96,400 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Integra LifeSciences were worth $941,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of IART. Hsbc Holdings PLC acquired a new position in Integra LifeSciences in the 4th quarter valued at about $879,000. Tejara Capital Ltd lifted its position in Integra LifeSciences by 42.6% during the fourth quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after acquiring an additional 51,300 shares during the last quarter. Systematic Financial Management LP boosted its holdings in shares of Integra LifeSciences by 4.5% during the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock worth $13,769,000 after acquiring an additional 48,094 shares during the period. Paradigm Capital Management Inc. NY boosted its holdings in shares of Integra LifeSciences by 50.6% during the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after acquiring an additional 1,347,700 shares during the period. Finally, Walleye Capital LLC grew its position in shares of Integra LifeSciences by 202.0% in the first quarter. Walleye Capital LLC now owns 218,595 shares of the life sciences company’s stock valued at $2,059,000 after purchasing an additional 146,203 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $16.65 on Monday. The business has a fifty day moving average price of $17.70 and a two-hundred day moving average price of $13.47. The stock has a market capitalization of $1.29 billion, a PE ratio of -184.98, a P/E/G ratio of 1.40 and a beta of 1.21. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. Integra LifeSciences Holdings Corporation has a fifty-two week low of $8.70 and a fifty-two week high of $20.49.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on IART. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Thursday, June 18th. Wells Fargo & Company lifted their target price on Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price for the company. Wall Street Zen downgraded shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Truist Financial lifted their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $18.86.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.